alexa PDGFRα Signaling Strength Confers Sensitivity To Vinblastine In Glioblastoma | 60842
ISSN: 2471-8556

Oncology & Cancer Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

15th World Congress on CANCER THERAPY, BIOMARKERS & CLINICAL RESEARCH

Al Charest
Beth Israel Deaconess Medical Center Cancer Center, USA
Keynote: Oncol Cancer Case Rep
DOI: 10.4172/2471-8556.C1.001
Abstract
The PDGF Receptor alpha is overexpressed and activated in a substantial number of Glioblastoma (GBM) tumors. Although the activation of PDGFRα in GBM is chronic in nature, our knowledge of PDGFR signaling pathways is largely derived from acute stimulation studies, which are less representative of the clinical setting. In order to decipher the identity and clinical significance of sustained PDGFRα signaling during tumorigenesis and to reveal therapeutic vulnerabilities, we created a novel genetically engineered conditional mouse model based on genomic events that are observed in patients, that is the overexpression of PDGFRα and its chronic activation by PDGF-A ligand in the context of loss of function of the p53 tumor suppressor gene. To broaden its clinical relevance, we created our model system with a titratable expression of PDGF-A, which is specific for PDGFRα homodimers. De novo intracranial PDGF-A;PDGFRα tumors arise in these mice with full penetrance and short latency and display histological and molecular features that are consistent with Proneural GBMs. Tumor growth in animals was intimately related to the levels of PDGF-A ligand expression, suggesting differences in cellular signaling in tumors with low and high levels of activated receptors. Indeed, global phospho- (pTyr, pSer/pThr) and total proteomic analyses on cells derived from PDGFRα-positive GBMs revealed that the strength and utilization of specific signaling pathways are dependent on the levels of PDGFRα activation. Further investigation of these pathways unveiled a role for the microtubule binding protein Stathmin 1 (STMN1) in the vulnerability of these GBM cells to the microtubule-disrupting drug vinblastine. Our results open the possibility that GBM patients whose tumors express active PDGFRα could benefit from treatments with vinca alkaloid type of therapeutic agents. Our observations also argue strongly for the development of inhibitors of STMN1 function for the treatment of PDGFRα positive GBMs.
Biography

Alain Charest, MSc, PhD is an Associate Professor in the Department of Medicine at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Dr. Charest received his postgraduate degrees at McGill University, Montreal, Canada. The focus of the Charest laboratory is on leveraging clinically relevant genetically engineered mouse models of primary malignant brain cancer to study central aspects of gliomagenesis and molecular responses to therapeutic interventions. Recent work from the Charest lab involves studies on how PDGFRa signaling strength confers sensitivity to chemotherapeutic agents in Glioblastoma Multiforme.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7